ommended to 366 patients (48.1%) after diagnosis at our institute in cases of: 1) multiple hemorrhages; 2) lesion size ≥ 2 cm; 3) severe or progressive symptoms; 4) acute or subacute hemorrhage with significant mass effect; or 5) exophytic lesions or lesions abutting the pial or ependymal membrane that were accessible. Conservative management was recommended to 395 patients (51.9%) if 1 of the following criteria was met: 1) the patient displayed a nonhemorrhagic or asymptomatic lesion; 2) the patient experienced only 1 hemorrhage with mild symptoms; 3) the lesion was small, deep-seated, and inaccessible; 4) resection would severely compromise neurological function; 5) the patient experienced functional recovery and disappearance or diminishment of the hematoma during the period from the initial onset to the diagnosis at our institute; or 6) the patient rejected surgery because of surgical risk. We did not recommend radiosurgery at our institute because of its unclear therapeutic effectiveness and potential for radiation injury. Moreover, the management strategy was individualized to each patient.
Of the 395 patients managed conservatively, 64 were excluded from further study due to the following: 1) the patient did not consent to follow-up (n = 21); 2) the patient was previously treated (with surgery or radiotherapy) prior to referral to our institute (n = 13); 3) the prospective follow-up duration was less than 12 months (n = 16); 4) a censoring event, including surgery, radiotherapy (particularly Gamma Knife surgery [GKS] ), or death from another unrelated cause occurred within 12 months after entering the study (n = 11); or 5) comorbidities were present involving the brainstem, peripheral nerves, or other eloquent lobes that might affect the accuracy of the evaluation of neurological function (n = 3). The remaining 331 patients (46.5% female) who consented to follow-up were included in the study. Data were collected, and informed consent was obtained from all study participants. The Beijing Tiantan Hospital Research Ethics Committee approved the study.
Initial Diagnosis
Upon the initial clinical consultation for brainstem CM treatment, each patient's chart was recorded, and the MR images were extensively reviewed. Two neuroradiologists independently reviewed each MR image to diagnose the brainstem CM based on the accepted criteria. 21, 25 Data regarding the lesion included the anatomical location (side and depth), 7 size (based on T1-weighted MR images), perilesional edema, Zabramski classification, 25 and any associated developmental venous anomaly (DVA). Cases of multiple cerebral CMs or brainstem CMs according to gradient-echo images were noted, and the characteristics of other coexisting lesions were recorded. Radiologically, hemorrhage was defined as an overt intralesional or extralesional hemorrhage based on the MRI at diagnosis, and the initial presentation was classified into 3 groups (Table  1) : recent hemorrhage with associated focal neurological deficits, hemorrhage without focal neurological deficits (headache, dizziness, or other deficits not directly related to the lesions), or nonhemorrhage regardless of symptoms. Prospective hemorrhage was defined as a clinical event (acute or subacute, new onset or worsening of a focal neurological deficit, or severe headache) corresponding to the anatomical location of the brainstem CM or the overt hemorrhage within or outside the lesion based on radiological evidence. 2, 3 A new clinical event with a timely MR image that was recorded outside of our institute was defined as a probable prospective hemorrhage. Clinical events without radiological evidence or morphological changes were not included in the analysis. Patients exhibiting a suspicious hemorrhagic ictus or a clinical event were recommended for radiological examination immediately to confirm the hemorrhagic episode; the images were further reviewed upon the clinical return visit, or they were mailed to our institute for further medical review on a remote consultation basis. A modified Rankin Scale 4 (mRS) score was used to evaluate neurological status.
Follow-Up
The inception point for each patient in the study was the diagnosis of brainstem CM at our institute. Followup evaluations were performed annually (clinical visits, mailed questionnaires, telephone interview, or family doctor) to monitor radiological changes based on MR images (if available). Information was collected regarding any treatment since the diagnosis, any subsequent treatment effects, changes in neurological function, time until complete improvement of each neurological deficit, the most recent mRS score, and the independent activities of daily living scale. Magnetic resonance imaging was recommended at 3 and 6 months after diagnosis and then once every 2 years thereafter, and MRI was performed using T1-and T2-weighted spin-echo or fast spin-echo sequences, and a T2-weighted gradient-echo sequence. Gradient echo was available at our institute beginning in January 1989. Patients diagnosed prior to January 1989 received an examination using a gradient-echo sequence at a later date to identify solitary or multiple intracranial CMs. During follow-up examination, a hemorrhagic event on MRI without clinical symptomatology was defined as an overt hemorrhage inside or outside of the lesion based on at least 2 comparable radiological examinations revealing a change in lesion size and signal intensity. The presence of a dark halo surrounding the CM based on the gradient-echo sequence was not considered to be sufficient for the diagnosis of a hemorrhagic ictus. 16 
Statistical Analysis
The prospective annual hemorrhage rate was calculated as the number of hemorrhages divided by the duration (in years) of follow-up per patient and was evaluated based on the category of each patient's initial presentation. Based on the most recent evaluation, univariate and multivariate Cox regression analysis was performed to estimate the hemorrhage and functional recovery risks, which were further illustrated using the Kaplan-Meier method. All potential risk factors are noted in Table 2 . Analysis of hemorrhage-free survival began on the date of the initial presentation and ended on the date of the earliest rehemorrhage or the date of censoring (most recent evaluation, death, complete resection, or radiosurgery), whichever occurred first. The cumulative duration until functional recovery began on the date of the most recent hemorrhage and continued until the date of complete recovery (mRS score of 0) or the date of censoring, whichever occurred first. The rate of complete symptom improvement was analyzed for the following deficits in terms of quality of life: cranial nerves III-VII, IX, and X; ataxia; motor deficits; and sensory deficits. The analyses were performed using SPSS Statistical Package software (version 19.0, IBM) with the significance set at p < 0.05 and using confidence interval analysis software. * In this group (n = 82), to avoid bias caused by the small number of patients, the patients without focal neurological deficit (FND; n = 18) were not classified as an independent subgroup but were instead combined with the patients with FND (n = 64). † χ 2 test. ‡ One-way ANOVA. § p < 0.05. ¶ Four cases were unavailable. ** Three cases of Zabramski classification IV were noted; for statistical analysis, the lesions classified as Type III and IV were placed into 1 group.
† † Wilcoxon signed-rank test. ‡ ‡ Kruskal-Wallis test.
Results
The mean patient age at the initial presentation was 36.2 years (range 5-67 years). The patient demographics are described in Table 1 . Most of the lesions involved the pons (173, 52.3%). Upon initial presentation, 139 patients (42.0%) presented with an acute overt hemorrhage, 110 (33.2%) with a subacute hemorrhage, and 82 (24.8%) with no overt hemorrhage. Among all patients, 279 (84.3%) exhibited focal neurological deficits that corresponded to the anatomical location of the lesion, 55 (16.6%) presented with symptoms unrelated to the brainstem CM, and 7 (2.1%) were diagnosed without any deficits. Primary deficits in the patients with symptomatic brainstem CMs included long tract impairment (n = 254, 76.7%), cranial nerve palsy (n = 242, 73.1%), and unrelated symptoms (n = 173, 52.3%). The mean mRS score at the time of diagnosis was 2.4 ± 1.3 (score 0, n = 7; score 1-2, n = 174; and score 3-5, n = 150).
The mean follow-up duration for all 331 patients was 6.5 years (range 1.0-28.6 years, 2151.3 total patientyears). Follow-up MR images were available for 272 patients (82.2%), and the remaining patients that did not present with a symptomatic rehemorrhage did not receive an MRI re-examination. Twenty patients (6.0%) were lost to long-term follow-up, and the mean duration from the date of diagnosis at our institute until the date when they were lost to follow-up was 4.8 years (range 1.2-21.6 years). Overall, 31 patients (9.4%) underwent GKS that was performed at other hospitals but not at the suggestion of the senior author of our institute, and 63 patients (19.0%) underwent resection according to the aforementioned surgical indications. All patients were censored at the time that they were provided treatment, and the mean untreated follow-up duration in patients receiving surgery or GKS was 5.5 years (range 1.3-22.5 years) and 8.4 years (range 1.5-20.0 years), respectively. Based on the few number of deaths and the low rate of morbidity, which was insignificant and acceptable, we defined the therapy as successful if patients could survive free of future hemorrhage at the same lesion location during their remaining long lifespan after treatment. Alternatively, the therapy was defined as unsuccessful if patients suffered from rehemorrhage after treatment. Three conservatively managed patients (0.9%, 95% CI 0.3-2.6) died due to the brainstem CM, and 3 patients died due to unrelated diseases following release from the hospital after the initial presentation.
Prospective Hemorrhage
Overall, 185 prospective symptomatic hemorrhages (161 definite and 24 probable) occurred in 131 patients (39.6%), and 35 (10.6%) experienced multiple prospective hemorrhages (22 patients experienced 2 episodes, 7 experienced 3 episodes, and 6 experienced 4 episodes). There was a trend toward multiple prospective hemorrhages in the patients initially presenting with hemorrhage with focal neurological deficits (12.1%) compared with those patients initially presenting with nonhemorrhage (7.3%, p = 0.235, χ 2 test; Table 1 ), although this result was below the level of significance. For the first prospective hemorrhage, 38 events (29.0%) occurred within 1 year after the diagnosis and 62 events (47.3%) occurred within 2 years. The median intervals from the diagnosis to the first prospective hemorrhage and from the first to the second prospective hemorrhage were 25.5 and 24.9 months, respectively.
The overall prospective annual hemorrhage rate was different between the 3 groups (χ 2 = 11.418, p = 0.003; Table 3 ), and the difference between the patients initially presenting with hemorrhage with focal neurological defi- Univariate analysis revealed significant predictors of future hemorrhage, including female sex, initial presentation with hemorrhage, perilesional edema, and a lower Zabramski classification (Table 2) . Initial presentation with a focal neurological deficit did not increase the risk of hemorrhage after the results were stratified based on the initial hemorrhage. Furthermore, upon multivariate analysis, female sex (HR 1.445, 95% CI 1.016-2.054, p = 0.041), experiencing a prior hemorrhage (HR 1.277, 95% CI 1.025-1.590, p = 0.029), and perilesional edema (HR 1.830, 95% CI 1.254-2.669, p = 0.002) continued to be significant predictors (Figs. 1A-C) , but a lower Zabramski classification (HR 1.024, 95% CI 0.718-1.461, p = 0.896) and older age (HR 1.074, 95% CI 0.944-1.221, p = 0.277) were no longer significant. The prospective hemorrhage-free survival rate was 92.9% at 6 months, 87.2% at 1 year, 53.0% at 5 years, 23.9% at 10 years, and 10.1% at 15 years (Fig. 1D) .
Untreated Functional Outcome
We focused on the complete recovery rate of neurological function (final mRS scores of 0) over time and limited the analysis of this outcome to the first 5 years. Although follow-up evaluations beyond the first 5 years were available, complete recovery did not occur during that period. The complete recovery rates in patients experiencing none, 1, or more than 1 prospective hemorrhage were 37% (74/200), 17.7% (17/96), and 11.4% (4/35), respectively; the reduction in complete recovery rates was significant (χ 2 = 13.541, p = 0.001). The overall cumulative survival rate with complete recovery was 17.1% at 3 months, 24.1% at 6 months, 29.1% at 1 year, and 30.3% at 2 years; thereafter, the rate remained at 30.3% (Fig.  2A) . The mean and median durations until complete recovery were 4.1 months (95% CI 3.4-4.9 months) and 3.0 months, respectively. The opportunity for complete recovery occurred primarily within the first 18 months after the most recent hemorrhage and became rare thereafter.
The most recent mRS score of the patients initially presenting with hemorrhage with focal neurological deficits was worse than that of the other 2 groups (χ 2 = 20.524, p < 0.001; Table 1 ). The mean of the most recent mRS score of patients experiencing none, 1, 2, or more than 2 prospective hemorrhages was 1.0, 1.6, 2.1, and 3.2, respectively. Compared with the mRS score at diagnosis, the most recent mRS score of the untreated patients (mean 1.3 ± 1.4, range 0-6; score 0, n = 95; score 1-2, n = 173; score 3-5, n = 57; score 6, n = 6) was significantly improved (Z = -10.513, p < 0.001). In addition, 198 patients (59.8%) improved, 109 (32.9%) stabilized, and 24 patients (7.3%) worsened (Fig. 2B) (Fig. 1D) . Moreover, the overall mean mRS score further improved to 1.2 ± 1.3 if we included the postoperative mRS scores from the surgically treated patients (Fig. 2B) . The factors associated with complete recovery, as determined by univariate analysis (Table 2) , were included for multivariate analysis. The following factors remained statistically significant as favorable: no prospective hemorrhage (HR 1.958, 95% CI 1.326-2.892, p = 0.001) (Fig. 2C The complete improvement rate was similar among patients suffering from cranial nerve palsy (χ 2 = 0.907, p = 0.923; Fig. 2E ). The complete improvement rate was highest for dysdipsia (86.2%, 50/58), followed by dysphagia (78.6%, 33/42), facial numbness (77.7%, 87/112), diplopia (76.3%, 90/118), and facial palsy (75.3%, 55/73; the relationship between the complete recovery rate of facial palsy and the House-Brackmann score was not evaluated. The complete improvement rates of dysarthria (71.9%, 46/64), paresthesia (64.4%, 121/188), motor weakness (61.4%, 86/140), and walking deficit (63.4%, 97/153) were similar (χ 2 = 1.005, p = 0.800), and these complete improvement rates were significantly greater than that of ataxia (43.4%, 23/53; χ 2 = 11.258, p = 0.024; Fig. 2F ). The estimated median survival time until complete recovery is indicated in Fig. 2 . Complete improvement of these deficits only occurred within the first 5 years after the most recent hemorrhage.
Outcomes of Different Treatment Modalities
The patient demographics, categorized by treatment modalities, are detailed in Table 4 . In 31 patients receiving GKS, the mean margin dose and mean maximum dose was 14.3 Gy (range 10-17 Gy) and 25.2 Gy (range 20-33 Gy), respectively. Of the 63 surgically treated patients, complete resection was achieved in 61 patients (96.8%). At the most recent evaluation, the postsurgical hemorrhage-free survival rate was significantly better than that of observation alone (log rank = 17.319, p < 0.001) or GKS (log rank = 18.089, p < 0.001), but the difference between the latter 2 treatment modalities was not significant (log rank = 0.016, p = 0.901; Fig. 3 ). The posttreatment annual hemorrhage rate of patients undergoing observation alone (9.4%) or GKS (7.6%) was similar (χ 2 = 0.485, p = 0.486), and both groups exhibited a statistically higher annual hemorrhage rate than that of surgically treated patients (0.4%; p < 0.001). At the most recent evaluation, the mean mRS score of patients undergoing observation alone (score 0.9) was better than that of patients treated with surgery (score 1.6, p < 0.001) or GKS (score 2.2, p = 0.001; Table 4 ).
Discussion
Although extensive research has characterized the risk factors and clinical course of cerebral CMs, 3,9 the natural history of brainstem CMs is undefined. Given the commonly aggressive and devastating pathologies of brainstem CMs relative to their lobar counterparts, we identified the predictors of prospective hemorrhage and Kaplan-Meier analysis illustrating the relationships between prospective hemorrhage-free survival and sex (A), perilesional edema (B), and initial presentation (C), and showing that female sex (A), perilesional edema (B), and initially presenting with a hemorrhage (C) are risk factors for prospective hemorrhage. D: Kaplan-Meier analysis illustrating the prospective hemorrhage-free survival in all patients and the cumulative survival including or excluding patients who died of other unrelated causes (DOO). The analysis confirmed that only a few patients died due to prospective hemorrhage, but it demonstrated the trend that some patients could survive free of prospective hemorrhage up to the most recent long-term follow-up. EMST = estimated median survival time; FND = focal neurological deficit.
Fig. 2.
Graphs showing improvement in neurological function and predictors for complete recovery. A: Kaplan-Meier analysis illustrating the overall cumulative survival with complete recovery for all patients. B: Box plot illustrating the overall recent outcome categorized by the initial mRS score. Circles indicate outliers. C and D: Kaplan-Meier analyses illustrating the favorable effects of experiencing no prospective hemorrhage (C) and small lesion size (D) on complete recovery. The analysis indicated that complete recovery primarily occurred within 18 months and that the rate of complete recovery decreased due to increased hemorrhagic episodes (C) and increased lesion size (D). E: Kaplan-Meier analysis illustrating the cumulative survival with complete recovery in patients with cranial nerve (CN) deficits, including diplopia, facial numbness, cranial nerve VII palsy, dysdipsia, and dysphagia, with estimated median survival times of 6.0, 6.0, 6.2, 6.0, and 4.8 months, respectively. F: KaplanMeier analysis illustrating the cumulative survival with complete recovery in patients with ataxia, dysarthria, paresthesia, motor weakness, and walking dysfunction; the estimated median survival times for the last 4 deficits were 9.0, 9.7, 10.0, and 9.5 months, respectively. The outcome of ataxia was significantly poorer than the other 4 symptoms.
functional outcomes and found that the overall outcome was acceptable. The results of this study suggested that approximately 20% of brainstem CMs exhibited a malignant clinical course. The probability of complete recovery tended to decrease over time, and patients initially presenting with hemorrhage with focal neurological deficits were likely to experience a high annual hemorrhage rate and poor outcomes.
Hemorrhage Risk
We used relatively strict patient selection criteria and a stringent definition of symptomatic overt hemorrhage that was comparable to prior studies 2, 3, 19, 22 because a lax definition not including morphological changes or radiological images would overestimate the hemorrhage rate, particularly for patients with multiple brainstem CMs. Otherwise, the psychological bias of anticipating a potential hemorrhage would intuitively cause the association of any symptoms (such as headache) with brainstem CMs in the absence of imaging. To avoid selection bias, patients undergoing surgery 12 months after entering the study were included in this study because these patients represented a majority of those with brainstem CMs involved in a malignant clinical course.
Many studies have identified the adverse effects of female sex, 1, 19, 22 prior hemorrhage, 1, 3, 9, 14, 15, 20 location (nonlobar, 6 infratentorial, 18 or deep), 20 and age (< 40 years) 1 ; the risk factors of female sex and prior hemorrhage were consistent with our results. However, a study of the natural history of brainstem CMs by Kupersmith et al. 16 failed to confirm these rehemorrhage risk factors. Possible explanations for our result that perilesional edema increased the risk of hemorrhage include impaired venous drainage, vessel connections between the lesions and the surrounding tissue, and infiltration of the lesions into the brainstem. We failed to identify a modifiable risk factor, but we did find that hemorrhage occurred in 11 patients within 12-24 hours after drinking alcohol (n = 5) or heavy exercise (n = 6). Heavy exercise might lead to increased systemic blood pressure, and delayed cerebral autoregulation could possibly cause the initial short-term increase in mean cerebral blood flow rate, which might lead to hemorrhage of CMs because the lesions lacked mural elements of mature vascular structures. Alcohol intake might result in acute vasodilation followed by increased mean cerebral blood volume, triggering a rise in the pressure of the endothelium-lined sinusoidal chambers of the lesion. Due to the small sample size of this group, our interpretation remains speculative, and further investigation is necessary.
Although the annual hemorrhage rate mildly decreased over time in patients initially presenting with hemorrhage with focal neurological deficits and in all patients, the risk did not decline remarkably, in contrast with prior studies of hemorrhage clustering. 5, 9 This result was most likely caused by the precarious locations of the lesions, which were more sensitive to microhemorrhage and referral bias if more patients had intrinsic rehemorrhage risk.
Functional Outcomes
A prior study found that 37% of patients with cerebral CMs recovered completely; this result was slightly better than the rate in our study (28.7%). 20 The percentage of improved or unchanged functional outcomes was retrospectively reported in relatively small cohorts and ranged from 46.7% to 95.7%. 10, 16, 23 This study demonstrated that an initial small lesion size, no prospective hemorrhage, and younger age contributed to promote complete recovery. These findings were interpreted as implying that a significant space-occupying effect, cumulative impairment caused by repeated hemorrhages, and advanced age with decreasing potential of rehabilitation or functional compensation would delay or even inhibit functional improvement. The initial mRS score at diagnosis was not considered to be a predictor because the baseline neurological function might have changed with each additional hemorrhage.
The classification of the initial presentations was useful for predicting the hemorrhage risk and the final neurological function (Tables 1 and 3) . The period to attain complete recovery to a mRS score of 0 ( Fig. 2A) was significantly limited to the first 18 months among a minority of patients (28.7%). Although it was assumed that the neurological function deficits would improve gradually if the patients were provided more time, few patients completely improved after the optimal period. Complete improvement of these respective symptoms (Fig. 2E and  2F ) was attained primarily within the first 12 months, but improvement rarely occurred after the first 5 years and exhibited similar estimated median survival time values, except for that of ataxia, which was less optimistic.
The overall outcome prior to treatment was not as malignant as previously estimated, and it further improved after surgery (Fig. 2B) . Surgery was not necessary for all brainstem CMs but was required for patients who exhibited surgical indications and required intensive care. 24 Additionally, we postulated that favorable outcomes of either conservative observation or resection could be achieved in select patients if they were carefully recommended for a treatment strategy based on their potential risks and initial presentations.
Limitations of the Study
This study was performed based on clinical presentation, MR images, and strict patient selection methods using a long study period , during which time neuroradiographic techniques evolved. This study compared the different treatments of observation, surgery, or GKS, but this comparison was subject to inherent selection bias. Therefore, we recommend that a prospective, randomized, controlled, multicenter population-based study be performed to expand upon the results of this study and to compare different treatment modalities. Systemic hypertension at diagnosis should also be considered in any future study. Presently, 90 additional brainstem CM cases have been included in this ongoing study. With an increased number of patients and a longer followup duration, our study will further minimize the inherent referral bias, confirm the accuracy of predictors and outcomes, and provide great internal validity for specific extrapolation to the patient population.
Conclusions
This study identified the risk predictors for prospective hemorrhage and functional outcomes of brainstem CMs and provided an estimated prospective annual symptomatic hemorrhage rate. These findings would be useful for clinicians to compare with analogous studies and to adopt reasonable treatments for their patients. These results warrant future studies to verify the accuracy of the risk factors and to establish an optimal therapeutic modality to improve brainstem CM patient outcomes. Disclosure Fig. 3 . Kaplan-Meier analysis illustrating hemorrhage-free survival for different treatment modalities. Hemorrhage-free survival for the 3 treatment modalities was significantly different (log-rank = 17.987, p < 0.001). The outcome following surgery was better than that of GKS (logrank = 18.089, p < 0.001) or observation alone (conservative management; log-rank = 17.319, p < 0.001), but the difference between the latter 2 treatment modalities was not significant (log-rank = 0.016, p = 0.901).
The inset depicts the same data on an enlarged segment of the x-axis.
